Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat in INI1-Negative Tumors or Synovial Sarcoma
NCT02601950Phase 2Completed
- Sponsor
- Epizyme, Inc.
- Start
- Dec 2015
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of tazemetostat in malignant rhabdoid tumor (MRT), synovial sarcoma (SS), epithelioid sarcoma (ES), chordoma, renal medullary carcinoma (RMC), sponsored by Epizyme, Inc.. Started Dec 2015; status: completed.
02
Drugs
tazemetostat
03
Conditions
malignant rhabdoid tumor (MRT)synovial sarcoma (SS)epithelioid sarcoma (ES)chordomarenal medullary carcinoma (RMC)
Beyond the preview
Go deeper on NCT02601950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601950.